echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > After the acquisition of Boan biology, the battle effectiveness of LVYE pharmaceutical has increased by one level

    After the acquisition of Boan biology, the battle effectiveness of LVYE pharmaceutical has increased by one level

    • Last Update: 2019-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 1, LVYE pharmaceutical announced the acquisition of 98% equity of Shandong Boan Biotechnology Co., Ltd., and obtained all intellectual property rights of the latter, such as antibody pipeline project, patent and other intellectual property rights, as well as antibody screening platform, antibody production platform and other assets According to the agreement, green leaf pharmaceutical will pay the related fees in three stages LVYE pharmaceutical is well known in the field of "small molecule preparation innovation" and "internationalization", and is in the forefront For example, the new drug market application (NDA) of risperidone sustained release microspheres for injection (ly03004) submitted by 505b (2) route in the United States has passed the pre market approval inspection (PAI) of FDA But in the field of biological medicine, the strength of green leaf pharmaceutical is not outstanding Prior to that, LVYE pharmaceutical has introduced 4 bio similar drugs from Boan bio for two times in August 2017 and December 2018 (refer to Avastin, Prolia, xgeva and eyla respectively), and also reached exploratory cooperation and car-t therapy development cooperation with Excel biopharm, elpis biopharm and other U.S cutting-edge biological companies on the next generation tumor immunotherapy antibody in 2018 However, these transactions as a whole seem more like green leaf's early exploration of technology transformation and upgrading around the "innovation" strategy The acquisition of Boan biological, the meaning behind it is much more far-reaching than its previous actions in the field of biological medicine The most direct effect is that LVYE pharmaceutical has an integrated industrial capacity from discovery, screening, research and development, production and sales in the field of antibody biopharmaceutics Let's analyze the logic behind the deal Biological drugs, especially antibody drugs, are becoming more and more important in the global drug market According to the latest statistics of financial statements of the company, in the first half of 2019, 12 seats are occupied by macromolecular biological drugs such as antibody / fusion protein, vaccine and insulin, with a total sales revenue of 46.372 billion US dollars, accounting for 64.4% of the total revenue of the top 20 drugs With the rapid growth of some tumor immunotherapeutics, these figures will continue to rise Source: company financial report, medicine magic cube According to the Sullivan research report of global consulting company, the global market scale of biological preparations has reached US $261.8 billion in 2018 In recent years, China's biopharmaceutical market has also ushered in a big outbreak, mainly reflected in: 1) with the return of talents and the influx of capital, China's new tumor immunotherapy projects, car-t cell therapy projects and the number of related clinical trials are now in the forefront of the world 2) At present, three domestic monoclonal antibodies of PD1 have been approved, and the large-scale speed and quarterly sales performance after being put on the market are outstanding, which breaks the previous understanding that monoclonal antibodies are not sold in China, and makes you see the potential of the domestic biological drug market 3) Two domestic bio similar drugs (Fuhong Hanlin rituximab and baiaotai Adamu mAb) have been approved, which makes the bio medicine market more lively It can be judged that Biopharmaceutics will always be the focus of attention in the industry, especially with the continuous deepening of everyone's scientific understanding of disease and the continuous progress of biotechnology, biopharmaceutics will be the strategic commanding point of the drug market, which is a very attractive cake for any pharmaceutical enterprise Biological medicine is a treasure that can be seen by everyone, but not by every enterprise This is mainly because biological drugs and small molecule drugs are two completely different drug development, production, pricing and sales systems, and the drug life cycle curve and competition strategy are not the same If the design and development ideas of clinical trials of biological drugs and chemical drugs are similar, the early drug discovery and the later commercial production quality control are quite different Even the fixed asset investment required by biological drug production line is much more expensive than that of small molecule drugs In recent two years, the transaction amount of Biopharmaceutics has continued to rise, which to some extent proves the determination of various pharmaceutical companies to enter the biopharmaceutical market At the end of last year, Baiji Shenzhou spent $430 million to acquire two dual antiviral drugs and technology platforms of zymeworks A few months ago, hausen pharmaceutical spent $220 million to reach a development and commercialization cooperation with viela bio in China for CD19 monoclonal antibody .. the popularity of biopharmaceutical M & A continues to grow, and it is believed that it will still be the mainstream of pharmaceutical M & A projects in the future Green leaf pharmaceutical plans to lay out biopharmaceuticals Although it is not difficult to obtain biopharmaceutical projects through introduction and promote subsequent clinical development, there is a lack of a complete biopharmaceutical R & D, production and quality control team before, and the supply and sales of biopharmaceutical commercialization in the later stage are inevitably restricted Therefore, through the acquisition of Boan bio, we can quickly build a sound bio pharmaceutical R & D, production system and a perfect bio pharmaceutical talent team, which is the most cost-effective way for green leaves in terms of time and strategic opportunities The acquisition of Boan biological, green leaf pharmaceutical in the field of biopharmaceutical fighting capacity has undergone qualitative changes On the one hand, Boan bio will greatly enrich the bio pharmaceutical project reserve of LVYE pharmaceutical In addition to the four previous antibody drugs that have entered phase III and phase I / II clinical respectively, LVYE pharmaceutical also obtained more biological similar drug projects from Boan biology, including PD-1 inhibitor opdivo, IL-17A inhibitor cosantyx, GLP-1 receptor agonist trulicity, etc.; in addition, Boan biology has more than 10 candidate innovations in research Biological products, which have the potential to become the first new drug and / or the best drug of the same kind in the same product and / or indication category Biological similar drug pipeline of Boan biology The innovative biological medicine pipeline of Boan biology From the perspective of pipeline combination, through the acquisition of Boan biology, LVYE pharmaceutical has created a new situation of biological similar medicine plus innovative medicine with two legs walking More importantly, considering that Boan biology has its own all human antibody transgenic mouse technology, phage display technology, nano antibody platform, and nearly 30 patent applications, etc., green leaf pharmaceutical will also have the self hematopoiesis ability of innovative biological drug projects in the future On the other hand, Boan biology has accumulated rich experience in antibody generation and lead compounds, cell line establishment and process development, pilot production and commercial production Through the acquisition of Boan bio, LVYE pharmaceutical can realize the comprehensive upgrade of bio pharmaceutical software and hardware in a short period of time It can not only continue to involve in clinical development, but also take into account the commercial production With the global sales network of LVYE pharmaceutical, the brand of LVYE pharmaceutical in the field of bio pharmaceutical is much better than before LVYE Pharmaceutical Co., Ltd is a first-class pharmaceutical enterprise in BD capacity in China At present, we can see that all its BD actions are carried out around two long-term strategies of "internationalization" and "innovation", and different directions of reinforcement are carried out in different stages of the company Green leaf will pay no more than 1446.7 million yuan (US $205.8 million) in installments for the acquisition of Boan bio The value of the transaction is not worth it, and it is also a more discussed issue We can see from the matching degree of the enterprise's own needs and the competitiveness in the industry First, the price performance of the transaction depends on the matching degree of the target and the buyer's demand Green leaf pharmaceutical needs to enter the field of Biopharmaceutics, and the most scarce resource is time Green leaf's past expertise in the preparation innovation of small molecule chemical drugs, if we start from scratch to build the biopharmaceutical industry chain and build a mature and perfect biopharmaceutical team management system, we may also miss the strategic opportunity period of this market The existing products, technologies and teams of Boan biology and LVYE pharmaceutical are complementary to each other A batch of biosimilar drugs that are expected to be promoted rapidly, together with a batch of innovative bio antibodies that are competitive in the medium and long term, can not only further expand the research and development pipeline of LVYE in bio medicine, but also realize the rapid integration of resources in various fields from research and development, production and marketing with LVYE The valuations of the non-profit biological companies listed in Hong Kong stock this year are basically more than 3 billion yuan: for the cornerstone pharmaceutical industry listed in February this year, there are 14 candidate products in the product pipeline at the time of listing, and the pre IPO valuation is about 7.44 billion yuan; for the maybo pharmaceutical industry listed in May, there are 9 products under research, and the pre IPO valuation is about 3.16 billion yuan Boan bio has 8 biological similar drugs under research, more than 10 biological innovative drugs under research, a package of patent applications, R & D and production platforms and teams For a biological company with a complete R & D system and production system at the current price, the price performance ratio is OK.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.